Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.50 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.50 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125450 | 0.96 | TRPV6 (0.53) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| Ammonia Solution, Strong SCHEMBL475909 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| Fluoride SCHEMBL5958527 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL7644960 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL500600 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL3164727 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL2197441 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL3887343 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL11103898 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL17036053 | 0.92 | TRPV6 (0.50) | TRPV6ORAI1ORAI2ORAI3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716799-A | Method for preparing cis-chiral-3-fluoro-4-hydroxypiperidine and derivatives thereof by reduction of organic borohydride metal reagent | 丽水绿氟科技有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-112939847-B | Method for preparing moxifloxacin intermediate (S, S) -2, 8-diazabicyclo [4,3,0] nonane | 台州市生物医化产业研究院有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112920184-B | Method for preparing moxifloxacin intermediate (S, S) -2, 8-diazabicyclo [4,3,0] nonane | 台州市生物医化产业研究院有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-7718792-B2 | Stereospecific reduction of sapogen-3-ones | PHYTOPHARM PLC (GB) | 2010-05-18 | — | — | US | claimed |
| EP-1558627-B1 | STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES | PHYTOPHARM PLC (GB) | 2010-03-03 | — | — | EP | claimed |
| CN-100486989-C | Stereospecific reduction of saporin-3-ones | PHYTOPHARM PLC (GB) | 2009-05-13 | — | — | CN | claimed |
| EP-1770092-A1 | Process for the preparation of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione | SMITHKLINE BEECHAM PLC (GB) | 2007-04-04 | — | — | EP | claimed |
| US-20060041119-A1 | Stereospecific reduction of Sapogen-3-ones | PHYTOPHARM PLC (GB) | 2006-02-23 | — | — | US | claimed |
| CN-1723218-A | Stereospecific reduction of saporin-3-ones | PHYTOTECH LTD (GB) | 2006-01-18 | — | — | CN | claimed |
| EP-1558627-A1 | STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES | Phytopharm Plc (GB) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037845-A1 | STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES | PHYTOPHARM PLC (GB) | 2004-05-06 | — | — | WO | claimed |
| US-6632947-B2 | By selective reduction of the exocyclic double bond in a benzylidene thiazolidine-2,4-dione moiety by complex hydride reducing agents such as lithium tri-sec-butyl borohydride | SMITHKLINE BEECHAM PLC (GB) | 2003-10-14 | — | — | US | claimed |
| US-20020042519-A1 | Process for the preparation of substituted thiazolidinedione | SMITHKLINE BEECHAM P.L.C. | 2002-04-11 | — | — | US | claimed |
| CN-1252065-A | Process for preparing substituted thiazolidinedione | SMITHKLINE BEECHAM PLC (GB) | 2000-05-03 | — | — | CN | claimed |
| EP-0970063-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1998037073-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE | SMITHKLINE BEECHAM PLC (GB) | 1998-08-27 | — | — | WO | claimed |
| US-20250333413-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12421193-B2 | GPR52 modulators and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-4517227-A | Forming of thick-layer, hybrid electronic printed circuits | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-05-14 | — | — | US | disclosed |
| US-4085267-A | Process for the suspension polymerization of vinyl chloride with low polymer buildup | THE B. F. GOODRICH COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333413-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | SLC18A2, SLC6A2, SLC18A1 | TRPV6 1544/4885ORAI1 3613/4885ORAI2 2261/4885 |
| US-20020042519-A1 | Process for the preparation of substituted thiazolidinedione | TALDO1, CYP11B1, CYP11B2 | TRPV6 1844/4885ORAI1 4584/4885ORAI2 4735/4885 |
| US-20060041119-A1 | Stereospecific reduction of Sapogen-3-ones | HSD3B2, HSD3B1, HSD17B7 | TRPV6 2493/4885ORAI1 3135/4885ORAI2 734/4885 |
| US-12421193-B2 | GPR52 modulators and methods of use | GPR52, GPR68, GPR35 | TRPV6 317/4885ORAI1 1156/4885ORAI2 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.